Working… Menu
Trial record 3 of 5 for:    EMI-137

Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions (EAGLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03205501
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : November 5, 2020
Information provided by (Responsible Party):
dr. W.B. Nagengast, MD, University Medical Center Groningen

Brief Summary:

To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization and the ability for targeted biopsies. Optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. It is known that the biomarker c-Met is overexpressed in dysplastic and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target for molecular imaging.

Edinburgh Molecular Imaging Ltd (EMI) has developed a fluorescent tracer specifically targeting c-Met by labeling a small peptide to a fluorescent fluorophore: 'EMI-137'. The investigators hypothesize that when EMI-137 is administered intravenously, it accumulates in c-Met expressing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), enabling (early) cancer visualization using a newly developed fluorescent fiber-bundle. This hypothesis will be tested in the current pilot intervention study.

Condition or disease Intervention/treatment Phase
Barrett Esophagus Esophageal Cancer Dysplasia in Barrett Esophagus Drug: IV-administation of EMI-137 Device: Molecular Fluorescence Endoscopy platform Phase 1

Detailed Description:
See brief summary.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Molecular Fluorescence Endoscopy for the Detection of (Pre)Malignant Lesions in Barrett's Esophagus Using a Fluorescent Tracer 'EMI-137' Targeting c-Met: a Single-center Feasibility and Safety Study
Actual Study Start Date : February 9, 2017
Actual Primary Completion Date : March 25, 2019
Actual Study Completion Date : September 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Experimental: IV-tracer EMI-137
  • IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.
  • Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals.
Drug: IV-administation of EMI-137
Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
Other Name: Tracer administation

Device: Molecular Fluorescence Endoscopy platform
A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
Other Name: Fluorescence Endoscopy

Primary Outcome Measures :
  1. Tumor-to-background ratio that allows the in vivo detection of (pre)malignant lesions in patients with Barrett's Esophagus using molecular fluorescence endoscopy. [ Time Frame: Day 1 ]
    Calculation of the in vivo tumor-to-background ratio (> 1.5) based on fluorescence intensities in (pre)malignant lesions compared to surrounding healthy esophageal tissue.

  2. Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137. [ Time Frame: Up to day 3 ]

Secondary Outcome Measures :
  1. The correlation of fluorescence signals to histopathology from (pre)malignant lesions and surrounding normal esophageal tissue. [ Time Frame: Up to 1 year ]
  2. Identification of fluorescence lesions and correlation with histopathology on subsequent biopsies in the resection surface after endoscopic mucosal resection. [ Time Frame: Up to 1 year ]
  3. Quantification of fluorescence signals in vivo and ex vivo of (pre)malignant lesions and normal esophageal tissue using multi-diameter single-fiber reflectance single-fiber fluorescence (MDSFR-SFF) spectroscopy. [ Time Frame: Up to 1 year ]
  4. Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy. [ Time Frame: Up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years, eligible for a diagnostic and/or therapeutic endoscopy;
  • At least a suspicion of low grade dysplasia (LGD) based on a prior endoscopy;
  • World Health Organization (WHO) performance score of 0-2;
  • Written informed consent;
  • Mentally competent person that is able and willing to comply with study procedures;
  • For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs or are less than 2 years post-menopausal:

    • A negative serum pregnancy test prior to receiving the tracer;
    • Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.

Exclusion Criteria:

  • Pregnancy or breast feeding;
  • Advanced stage EAC patient not suitable for endoscopic resection;
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent;
  • Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last three months prior to the start of the treatment
  • The subject has been included previously in this study or has been injected with another investigational medicinal product within the past six months.
  • History of myocardial infarction (MI), Transient Ischemic Attack (TIA), CerebroVascular Accident (CVA), pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment.
  • The subject had any significant change in their regular prescription or non-prescription medication between 14 days and 1 day prior to Investigational Medicinal Product (IMP) administration. Occasional use of analgesics, such as non-steroid anti-inflammatory drugs and/or paracetamol, was permitted at the discretion of the investigator. Use of hormonal contraceptives is permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03205501

Layout table for location information
University Medical Center Groningen
Groningen, Netherlands, 9713GZ
Sponsors and Collaborators
University Medical Center Groningen
Layout table for investigator information
Principal Investigator: W.B. Nagengast, MD, PhD, PharmD University Medical Center Groningen
Principal Investigator: G.M. van Dam, MD, PhD University Medical Center Groningen
Layout table for additonal information
Responsible Party: dr. W.B. Nagengast, MD, Principle Investigator, University Medical Center Groningen Identifier: NCT03205501    
Other Study ID Numbers: NL59628.042.16
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: November 5, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by dr. W.B. Nagengast, MD, University Medical Center Groningen:
Additional relevant MeSH terms:
Layout table for MeSH terms
Barrett Esophagus
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Precancerous Conditions